{"id":19626,"date":"2023-05-31T15:53:49","date_gmt":"2023-05-31T15:53:49","guid":{"rendered":"https:\/\/clinlabint.com\/?p=19626"},"modified":"2023-05-31T15:53:49","modified_gmt":"2023-05-31T15:53:49","slug":"sphere-fluidics-appoints-kenneth-hitchner-as-chairman-of-its-board-of-directors","status":"publish","type":"post","link":"https:\/\/clinlabint.com\/sphere-fluidics-appoints-kenneth-hitchner-as-chairman-of-its-board-of-directors\/","title":{"rendered":"Sphere Fluidics appoints Kenneth Hitchner as Chairman of its Board of Directors"},"content":{"rendered":"
\n

\r\n\"Bio-Rad<\/a>\r\n<\/p>\n<\/div><\/section><\/div>

<\/p>\n<\/div><\/section>
\n

Sphere Fluidics appoints Kenneth Hitchner as Chairman of its Board of Directors<\/h1>\/ in E-News<\/a> <\/span><\/span><\/header>\n<\/div><\/section>
\n

Sphere Fluidics, a company developing single cell analysis systems underpinned by its patented picodroplet technology, has appointed Kenneth Hitchner, BA MBA, as Chairman of its Board of Directors. The announcement follows a series of appointments to the Company\u2019s senior leadership team, as part of its ambitious global growth strategy.<\/h3>\n

<\/p>\n

With over 30 years in the healthcare industry, Ken brings extensive strategic advisory, M&A, underwriting and other transactional expertise. He spent much of his 28-year career at Goldman Sachs in the biopharmaceutical and medical device sectors; a member of the Global Management committee and Chairman and CEO of Asia Pacific, excluding Japan, from 2013 to 2019. Prior to this role, Hitchner was Goldman Sachs\u2019 Global Head of Healthcare banking and Global Co-Head of TMT banking. Before joining Goldman Sachs, Hitchner was a carrier-based fighter bomber pilot for the U.S. Navy. He is currently a Board member of publicly traded Wuxi Biologics and CStone Pharmaceuticals, and a senior advisor to Wuxi Apptec. Additionally, Hitchner is Chairman of HH&L, a healthcare focused specialty acquisition company listed on the NYSE, and Cydar Medical. He is also a senior advisor to early-stage venture capital firm Antler.<\/p>\n

\u201cSphere Fluidics is changing the face of cell line development. The Cyto-Mine platform has transformed single cell analysis and the productivity of biopharmaceutical discovery, maximizing researchers\u2019 productivity in finding rare or valuable cell variants that can lead to a life-changing medicine. I look forward to collaborating with the team as we drive the company forward in this exciting next phase of commercial growth,\u201d said Hitchner.<\/p>\n<\/div><\/section>
\n

\"\"<\/div><\/div><\/div>
\n